Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer

NCT00284258 is registered in ClinicalTrials.gov with Taiho Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT00284258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00284258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer
Lead sponsor
Taiho Pharmaceutical Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
January 31, 2006
Completion date
August 31, 2010
Enrollment
426 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer